Drug General Information (ID: DDIN8V2KT6)
Drug Name			Inotuzumab ozogamicin		Drug Info		Bedaquiline		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Antituberculosis Agents

Mechanism of Inotuzumab ozogamicin-Bedaquiline Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Inotuzumab ozogamicin				Bedaquiline
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Bedaquiline

Recommended Action
Management		Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration.

References
1	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.